Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis

Oncotarget

Volumn 5, Issue 10, 2014, Pages 3066-3075

  Huang, Qing Bo ^a   Ma, Xin ^a   Li, Hong Zhao ^a   Ai, Qing ^a   Liu, Shang Wen ^b   Zhang, Yu ^a   Gao, Yu ^a   Fan, Yang ^a   Ni, Dong ^c   Wang, Bao Jun ^a   Zhang, Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b The 303rd Hospital of PLA   (China)

^c ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Cell communication; Kidney neoplasms; Neoplasm metastasis; Signal transduction

Indexed keywords

ANGIOGENIC FACTOR; ENDOTHELIAL DELTA LIKE 4; GELATINASE B; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; DLL4 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER EPIDEMIOLOGY; CAPILLARY DENSITY; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HEMATOGENOUS METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; DISEASE COURSE; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSFECTION; YOUNG ADULT;

EID: 84902083897     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1827     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
2. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997; 80(7):1198-1220.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(6 Suppl 16):15-18.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-1186.
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82(1):4-6.
6. Al-Najar A, Al-Sanabani S, Korda JB, Hegele A, Bolenz C, Herbst H, Junemann KP and Naumann CM. Microvessel density as a prognostic factor in penile squamous cell carcinoma. Urol Oncol. 2010.
7. Yan M and Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 2007; 13(24):7243-7246.
8. Williams CK, Li JL, Murga M, Harris AL and Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006; 107(3):931-939.
9. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H and Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445(7129):776-780.
10. Kopan R and Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-233.
11. Tien AC, Rajan A and Bellen HJ. A Notch updated. J Cell Biol. 2009; 184(5):621-629.
12. Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, Malfertheiner P, Gasbarrini A, Romano M, Meyer RL, Genta RM, Fox JG, Boland CR, Bazzoli F and Ricciardiello L. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget. 2011; 2(12):1291-1301.
13. Ding XY, Ding J, Wu K, Wen W, Liu C, Yan HX, Chen C, Wang S, Tang H, Gao CK, Guo LN, Cao D, Li Z, Feng GS, Wang HY and Xu ZF. Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth. Oncogene. 2011.
14. Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi TP, Zhang Y, Gao Y, Fan Y, Ni D, Wang BJ, Li HZ and Zheng T. Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PLoS One. 2013; 8(6):e67294.
15. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005; 65(19):8690-8697.
16. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD and Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007; 104(9):3219-3224.
17. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006; 444(7122):1083-1087.
18. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD and Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006; 444(7122):1032-1037.
19. Thurston G, Noguera-Troise I and Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7(5):327-331.
20. Kaessmeyer S, Bhoola K, Baltic S, Thompson P and Plendl J. Lung cancer neovascularisation: Cellular and molecular interaction between endothelial and lung cancer cells. Immunobiology. 2013.
21. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H and Gomez-Manzano C. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget. 2010; 1(8):700-709.
22. Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L, Moserle L, Reboldi A, Favaro E, Mecarozzi M, Di Mario G, Screpanti I, Ponzoni M, Doglioni C and Amadori A. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res. 2009; 69(4):1314-1323.
23. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12(8):895-904.
24. Eric C. Umbreit R and Thompson H. Metastatic Potential of the Small Renal Mass: Why Can't We Agree? EUROPEAN UROLOGY. 2011; 40:4.
25. Kunkle DA, Crispen PL, Li T and Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007; 177(5):1692-1696; discussion 1697.
26. Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, Bernstein M, Coleman J, Dalbagni G, Touijer K and Russo P. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009; 182(1):41-45.
27. Egeblad M and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-174.
28. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ and Cho SH. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol. 2003; 44(5):560-566.
29. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001; 7(10):3113-3119.
30. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ and Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001; 158(2):735-743.
31. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R and Harris AL. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011.
32. ClinicalTrials.gov. A multiple-ascending-dose study of the safety and tolerability of REGN421 in patients with advanced solid malignancies. http://clinicaltrialsgov/ct2/show/NCT00871559. 2010.
33. ClinicalTrials.gov. A phase 1 dose escalation study of OMP-21M18 in subjects with solid tumors. http://clinicaltrialsgov/ct2/show/NCT00744562. 2010.
34. Li JL and Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci. 2009; 14:3094-3110.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-216.
36. Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang C, Zhu M, Zhang Y, Wang B, Ni D, Li H, Zheng T and Zhang X. High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One. 2012; 7(4):e35022.